DiaMedica Therapeutics Inc. (DMAC) Analyst Estimates Annual - Discounting Cash Flows
DMAC
DiaMedica Therapeutics Inc.
DMAC (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2018
12-30
2016
12-30
2015
12-30
Number of Analysts 2 3 4 5 0 0 None None None
Estimated Revenue
Low 39.6 13.88 2.75 54 0 0 0.5 3.66 3.66
Average 39.6 14.05 2.79 54 0 0 0.5 3.66 3.66
High 39.6 14.22 2.82 54 0 0 0.5 3.66 3.66
Estimated EBITDA
Low 0 0 0 0 0 0 0 0 0
Average 0 0 0 0 0 0 0 0 0
High 0 0 0 0 0 0 0 0 0
Estimated EBIT
Low 0 0 0 0 0 0 0 0 0
Average 0 0 0 0 0 0 0 0 0
High 0 0 0 0 0 0 0 0 0
Estimated Net Income
Low -27.07 -48.49 -42.42 -33.85 -30.15 -24.35 -33.54 -73.92 -73.92
Average -27.07 -31.72 -36.16 -29.31 -26.59 -23.94 -33.54 -73.92 -73.92
High -27.07 -14.95 -29.9 -24.77 -23.03 -23.53 -33.54 -73.92 -73.92
Estimated SGA Expenses
Low 0 0 0 0 0 0 0 0 0
Average 0 0 0 0 0 0 0 0 0
High 0 0 0 0 0 0 0 0 0
Estimated EPS
Low -0.67 -1.2 -1.05 -0.838 -0.746 -0.603 -0.83 -1.83 -1.83
Average -0.67 -0.89 -0.88 -0.756 -0.684 -0.593 -0.83 -1.83 -1.83
High -0.67 -0.37 -0.74 -0.613 -0.57 -0.582 -0.83 -1.83 -1.83
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program